RT Journal Article
SR Electronic
T1 Multi-modal single-cell sequencing identifies cellular immunophenotypes associated with juvenile dermatomyositis disease activity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.18.21263581
DO 10.1101/2021.09.18.21263581
A1 Neely, Jessica
A1 Hartoularos, George
A1 Bunis, Daniel
A1 Sun, Yang
A1 Lee, David
A1 Kim, Susan
A1 Ye, Chun Jimmie
A1 Sirota, Marina
YR 2021
UL http://medrxiv.org/content/early/2021/09/23/2021.09.18.21263581.abstract
AB Juvenile dermatomyositis (JDM) is a rare autoimmune condition with insufficient biomarkers and treatments, in part, due to incomplete knowledge of the cell types mediating disease. We investigated immunophenotypes and cell-specific genes associated with disease activity using multiplexed RNA and protein single-cell sequencing applied to PBMCs from 4 treatment-naïve JDM (TN-JDM) subjects at baseline, 2, 4, and 6 months and 4 subjects with inactive disease. Analysis of 55,564 cells revealed separate clustering of TN-JDM cells within monocyte, NK, CD8+ effector T and naïve B populations. The proportion of CD16+ monocytes was reduced in TN-JDM, and naïve B cells were expanded. Cell-type differential gene expression analysis and hierarchical clustering identified a pan-cell-type IFN gene signature over-expressed in TN-JDM in all cell types and correlated with disease activity. TN-JDM monocytes displayed an inflammatory state: CD16+ monocytes expressed the highest IFN gene score and differential protein expression of adhesion molecules, CD49d and CD56, compared to CD14+ inflammatory monocytes. A transitional B cell population expressing higher CD24 and CD5 proteins and an IFN-hi naïve B population were associated with TN-JDM and exhibited less CD39, an immunoregulatory protein. This data provides new insights into JDM immune dysregulation at cellular resolution and novel resource for myositis investigators.Competing Interest StatementC.J.Y. is a Scientific Advisory Board member for and hold equity in Related Sciences and ImmunAI, a consultant for and hold equity in Maze Therapeutics, and a consultant for TReX Bio. C.J.Y. has received research support from Chan Zuckerberg Initiative, Chan Zuckerberg Biohub, and Genentech.Funding StatementThis work was supported by Grant 2019124 from the Doris Duke Charitable Foundation, grants from the Cure JM Foundation, a grant from PREMIER, a NIH/NIAMS P30 Center for the Advancement of Precision Medicine in Rheumatology at UCSF (P30AR070155), and a CARRA Arthritis Foundation grant.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of California, San Francisco IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data associated with this study will be made available in the pertinent databases upon acceptance to a peer-reviewed journal.